REGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023PRNewsWire • 05/22/23
REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical PortfolioPRNewsWire • 05/16/23
REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational HighlightsPRNewsWire • 05/03/23
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual MeetingPRNewsWire • 05/02/23
REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational HighlightsPRNewsWire • 04/26/23
REGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitPRNewsWire • 04/18/23
REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular DystrophyPRNewsWire • 04/11/23
REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational HighlightsPRNewsWire • 02/28/23
Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium™PRNewsWire • 02/24/23
Additional Positive Interim Data from Phase I/II/III CAMPSIITE™ Trial of REGENXBIO's RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTMPRNewsWire • 02/22/23
REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational HighlightsPRNewsWire • 02/21/23
REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform ProcessPRNewsWire • 02/11/23
REGENXBIO Announces Presentation at the Virtual SVB Securities Global Biopharma ConferencePRNewsWire • 02/08/23
REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 ConferencePRNewsWire • 02/06/23
REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting PatientsPRNewsWire • 01/23/23
REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/03/23